Medical/Pharmaceuticals
TREEFROG THERAPEUTICS PICKS-UP BEST POSTER AWARD AT THE INTERNATIONAL SOCIETY FOR CELL & GENE THERAPY (ISCT) ANNUAL MEETING FOR THEIR CELL THERAPY PROGRAM IN PARKINSON'S DISEASE
- Treefrog will present two posters on their cell therapy program in
Parkinson's Disease and their proprietary encapsulation technology, C-Stem™ -
BORDEAUX, France, May 29, 2024 /PRNewswire/ -- TreeFrog Therapeutics
2024-05-29 06:00
1483
Metabolon Now Includes Spectral Data Files for All Global Discovery Panel Projects
MORRISVILLE, N.C., May 28, 2024 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced the availability of spectral data fil...
2024-05-28 21:00
1380
From Research to Practice: Prof. Gang Shen and Smartee's Contributions to the ASO Clinical Day 2024
SYDNEY, May 28, 2024 /PRNewswire/ -- Smartee Denti-Technology, a global leader in clear aligners and digital orthodontic solutions, demonstrated its commitment to transforming research into practical clinical applications at the ASO Clinical Day 2024.5.24. ASO is the largest dental specialist so...
2024-05-28 19:19
1364
Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies
* Synergistic collaboration to revolutionize age-related therapies worldwide * Deal valued at over $300 million USD for initial product MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an e...
2024-05-28 19:00
1352
Lifespin GmbH and Acıbadem Forge a Groundbreaking Metabolomics Partnership to Advance Personalized Medicine
ISTANBUL and REGENSBURG, Germany, May 28, 2024 /PRNewswire/ -- lifespin GmbH, a pioneer in health status detection software, has teamed up with Acıbadem University (ACU) and Acıbadem Healthcare Group (AHG) to launch a comprehensive precision medicine initiative, a significant stride towards revol...
2024-05-28 14:00
1424
Ovarian tissue transplantation is gaining ground for fertility preservation in young and old, with potential to offset adverse effects of menopause
MANILA, Philippines, May 28, 2024 /PRNewswire/ -- More than 10,000 women and girls around the world facing urgent treatments for cancers and other serious conditions that threatened their fertility have had their motherhood potential preserved by surgical removal and freezing of ovarian tissue. ...
2024-05-28 11:36
1526
Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA
SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2024-05-28 08:00
2579
Driving a consensus approach to improve the lives and fertility health of women stricken with endometriosis
MANILA, Philippines , May 27, 2024 /PRNewswire/ -- Specialists in reproductive health in theAsia Pacific region are advancing a pathfinding initiative to improve the lives of millions of women around the world who suffer from endometriosis. The debilitating condition affects up to 10 per cent ...
2024-05-27 13:00
1925
Chula Medicine Joins Forces with the Department of Thai Traditional and Alternative Medicine to Determine "Curcumin" as Effective Treatment for Dyspepsia as Modern Antacids
Chula
2024-05-27 11:00
2749
Telix Submits NDA for New Prostate Cancer Imaging Agent
MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) tothe United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit ("Kit") for th...
2024-05-27 07:21
1909
YS Biopharma Announces Name Change to LakeShore Biopharma
GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2024-05-24 19:30
2009
61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals
STOCKHOLM, May 24, 2024 /PRNewswire/ -- A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic kidn...
2024-05-24 19:00
2935
Menarini Group Presents Updated Data from ELECTRA and ELEVATE Combination Studies of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2024 Annual Meeting
* The ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options. * Updated results from the ELECTRA study, evaluating elacestrant in combination with abemaciclib regardless of metastatic site,show a sa...
2024-05-24 17:36
2549
Compassionate closure for those who are unable to fulfil hopes and expectations of fertility treatment
MANILA, Philippines, May 24, 2024 /PRNewswire/ -- Compassionate closure is a vital aspect of the holistic care of millions of people each year who are left with lost hopes and dreams of parenthood after assisted conception. In the dynamic and rapidly expanding field of assisted reproductive te...
2024-05-24 16:00
1986
United in Our Fight Against Cancer - New Frontier Group Acquires Hong Kong Integrated Oncology Centre
HONG KONG, May 24, 2024 /PRNewswire/ -- New Frontier Group (hereinafter referred to as "New Frontier") announces today that it has completed the acquisition of Hong Kong Integrated OncologyCentre (hereinafter referred to as "HKIOC"), a leading comprehensive private oncology medical platform. Thro...
2024-05-24 13:59
2710
CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website
* CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. * First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activ...
2024-05-24 13:00
2265
Busting fear barrier about hormone replacement therapy in new era of menopause management
MANILA, Philippines, May 24, 2024 /PRNewswire/ -- Millions of women around the world continue to suffer unnecessarily from the physical and psychological effects of the menopause because of "mistaken fears" about the risks and benefits of hormone replacement therapy. A world leader in human fe...
2024-05-24 09:00
1914
Antengene To Present One Oral and Four Abstracts at ASCO 2024
* Oral Presentation：a Phase II study of ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in patients with cervical cancer * Three Poster presentations: Phase I/II studies of ATG-031 (anti-CD24 monoclonal antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), and selinexor(XPO1 Inh...
2024-05-24 08:30
2882
Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024
Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5. PRINCETON, N.J. and SUZHOU, China, May 24, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharm...
2024-05-24 08:00
2317
ONCOCLÍNICAS APPROVES R$ 1.5 BILLION CAPITAL INCREASE
Operation aims to strengthen the Company's financial position and maintain growth strategy SAO PAULO, May 24, 2024 /PRNewswire/ -- Oncoclínicas&Co (B3: ONCO3), a leading oncology company headquartered inLatin America, has announced that the enterprise has approved a capital increase ofR$ 1.5 bil...
2024-05-24 06:41
1956
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5216
